课题基金 / 基金详情

ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA

ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
ONCONASE 与阿霉素治疗恶性间皮瘤
批准号：
6303004
负责人：
FRANCISCO ROBERT
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303004
关键词：
antineoplastics clinical research clinical trials doxorubicin human subject human therapy evaluation mesothelioma neoplasm /cancer chemotherapy

项目摘要

项目成果

FRANCISCO ROBERT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a multicenter randomized comparative phase III trial of Onconase vs. Doxorubicin in patients with maglignant mesothelioma (Part I). This study was revised on February 16, 1999 to include a randomization between Doxorubicin vs. Onconase + Doxorubicin. Primary side effects of Onconase were myalgias, arthralgias, fatigue and mild legidema. Side effects of chemotherapy were myelosuppression, alopecia , mild nausea/vomiting and mucositis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
海外基金